New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury

Frontiers in Pharmacology

Volumn 8, Issue JUN, 2017, Pages

  Cinausero, Marika ^a   Aprile, Giuseppe ^a,b   Ermacora, Paola ^a   Basile, Debora ^a   Vitale, Maria G ^a   Fanotto, Valentina ^a   Parisi, Giuseppe ^a   Calvetti, Lorenzo ^b   Sonis, Stephen T ^c,d,e  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b San Bortolo General Hospital   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e Biomodels   (United States)

Author keywords

Anticancer treatment; Gastrointestinal mucositis; Management; Oral mucositis; Pathobiology

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; AMIFOSTINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; ANTIOXIDANT; BLEOMYCIN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; HYDROXYUREA; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; OXALIPLATIN; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; RIDAFOROLIMUS; SUNITINIB; TAXANE DERIVATIVE; TEMSIROLIMUS; UNINDEXED DRUG; ZINC;

ANALGESIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; COLORECTAL CANCER; CRYOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DYSGEUSIA; ESOPHAGITIS; GASTROINTESTINAL MUCOSITIS; HEAD AND NECK CANCER; HOSPITAL COST; HUMAN; HYPERSENSITIVITY; KIDNEY CARCINOMA; LOW LEVEL LASER THERAPY; MEDICAL ASSESSMENT; MICROFLORA; MORBIDITY; MOUTH HYGIENE; MUCOSA INFLAMMATION; NEUROENDOCRINE TUMOR; NONHUMAN; ORAL MUCOSITIS; PATHOGENESIS; PRACTICE GUIDELINE; PROCTITIS; QUALITY OF LIFE; REVIEW; RISK FACTOR; STOMATITIS;

EID: 85020765770     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00354     Document Type: Review

References (144)

1. Abayomi, J., Kirwan, J., and Hackett, A. (2009). The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life. Eur. J. Oncol. Nurs. 13, 262-267. doi: 10.1016/j.ejon.2009.02.007
2. Abdel-Rahman, O., ElHalawani, H., and Essam-Eldin, S. (2016). S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opin. Drug Saf. 15, 5-20. doi: 10.1517/14740338.2016.1105959
3. Abdel-Rahman, O., and Fouad, M. (2015). Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev. Anticancer Ther. 15, 847-858. doi: 10.1586/14737140.2015.1047350
4. Adebahr, S., Schimek-Jasch, T., Nestle, U., and Brunner, T. B. (2016). Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Pract. Res. Clin. Gastroenterol. 30, 565-580. doi: 10.1016/j.bpg.2016.07.003
5. Ala, S., Saeedi, M., Janbabai, G., Ganji, R., Azhdari, E., and Shiva, A. (2016). Efficacy of sucralfate mouth wash in prevention of 5-fluorouracil induced oral mucositis: a prospective, randomized, double-blind, controlled trial. Nutr. Cancer 68, 456-463. doi: 10.1080/01635581.2016.1153666
6. Al-Ansari, S., Zecha, J. A. E. M., Barasch, A., de Lange, J., Rozema, F. R., and Raber-Durlacher, J. E. (2015). Oral mucositis induced by anticancer therapies. Curr. Oral Health Rep. 2, 202-211. doi: 10.1007/s40496-015-0069-4
7. Al-Dasooqi, N., Gibson, R. J., Bowen, J. M., Logan, R. M., Stringer, A. M., and Keefe, D. M. (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp. Biol. Med. 235, 1244-1256. doi: 10.1258/ebm.2010.010082
8. Al-Dasooqi, N., Sonis, S. T., Bowen, J. M., Bateman, E., Blijlevens, N., Gibson, R. J., et al. (2013). Emerging evidence on the pathobiology of mucositis. Support. Care Cancer 21, 2075-2083. doi: 10.1007/s00520-013-1810-y
9. Allison, R. R., Ambrad, A. A., Arshoun, Y., Carmel, R. J., Ciuba, D. F., Feldman, E., et al. (2014). Multi-institutional, randomized, double-blind, placebo-controlled trial to assess the efficacy of a mucoadhesive hydrogel (MuGard) in mitigating oral mucositis symptoms in patients being treated with chemoradiation therapy for cancers of the head and neck. Cancer 120, 1433-1440. doi: 10.1002/cncr.28553
10. Aprile, G., Rihawi, K., De Carlo, E., and Sonis, S. T. (2015). Treatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: a critical update. World J. Gastroenterol. 21, 11793-11803. doi: 10.3748/wjg.v21.i41.11793
11. Arbabi-kalati, F., Arbabi-kalati, F., Deghatipour, M., and Ansari Moghadam, A. (2012). Evaluation of the efficacy of zinc sulfate in the prevention of chemotherapy-induced mucositis: a double-blind randomized clinical trial. Arch. Iran. Med. 15, 413-417
12. Azizi, A., Alirezaei, S., Pedram, P., and Mafi, A. R. (2015). Efficacy of topical and systemic vitamin e in preventing chemotherapy-induced oral mucositis. Rep. Radiother. Oncol. 2:e796. doi: 10.5812/rro.2(1)2015.796
13. Barasch, A., Peterson, D. E., Tanzer, J. M., D'Ambrosio, J. A., Nuki, K., Schubert, M. M., et al. (1995). Helium-neon laser effects on conditioning-induced oral mucositis in bone marrow transplantation patients. Cancer 76, 2550-2556. doi: 10.1002/1097-0142(19951215)76:12<2550::AID-CNCR2820761222>3.0.CO;2-X
14. Baydar, M., Dikilitas, M., Sevinc, A., and Aydogdu, I. (2005). Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J. Natl. Med. Assoc. 97, 1161-1164
15. Blijlevens, N., and Sonis, S. (2007). Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-induced mucositis. Ann. Oncol. 18, 817-826. doi: 10.1093/annonc/mdl332
16. Boers-Doets, C. B., Epstein, J. B., Raber-Durlacher, J. E., Ouwerkerk, J., Logan, R. M., Brakenhoff, J. A., et al. (2012). Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17, 135-144. doi: 10.1634/theoncologist.2011-0111
17. Boers-Doets, C. B., and Lalla, R. V. (2013). The mIAS scale: a scale to measure mTOR inhibitor-associated stomatitis. Supp. Care Cancer 21(Suppl. 1), S140
18. Bonner, J. A., Giralt, J., Harari, P. M., Baselga, J., Spencer, S., Bell, D., et al. (2016). Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial. Eur. J. Cancer 64, 1-11. doi: 10.1016/j.ejca.2016.05.008
19. Bossi, P., Bergamini, C., Miceli, R., Cova, A., Orlandi, E., Resteghini, C., et al. (2016). Salivary cytokine levels and oral mucositis in head and neck cancer patients treated with chemotherapy and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 96, 959-966. doi: 10.1016/j.ijrobp.2016.08.047
20. Bossi, P., Lucchesi, M., and Antonuzzo, A. (2015). Gastrointestinal toxicities from targeted therapies: measurement, duration and impact. Curr. Opin. Support. Palliat. Care 9, 163-167. doi: 10.1097/SPC.0000000000000128
21. Bowen, J. M., Gibson, R. J., Keefe, D. M., and Cummins, A. G. (2005). Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 37, 56-62. doi: 10.1080/00313020400023461
22. Bowen, J. M., Gibson, R. J., and Keefe, D. M. K. (2011). Animal models of mucositis: implications for therapy. J. Support. Oncol. 9, 161-168. doi: 10.1016/j.suponc.2011.04.009
23. Campos, M. I. D. C., Campos, C. N., Aarestrup, F. M., and Aarestrup, B. J. V. (2014). Oral mucositis in cancer treatment: natural history, prevention and treatment. Mol. Clin. Oncol. 2, 337-340. doi: 10.3892/mco.2014.253
24. Cascinu, S., Fedeli, A., Fedeli, S. L., and Catalano, G. (1994). Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. Eur. J. Cancer. B. Oral Oncol. 30B, 234-236. doi: 10.1016/0964-1955(94)90003-5
25. Chansky, K., Benedetti, J., and Macdonald, J. S. (2005). Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103, 1165-1171. doi: 10.1002/cncr.20878
26. Chaveli-López, B. (2014). Oral toxicity produced by chemotherapy: a systematic review. J. Clin. Exp. Dent. 6, e81-e90. doi: 10.4317/jced.51337
27. Chaveli-López, B., and Bagán-Sebastián, J. V. (2016). Treatment of oral mucositis due to chemotherapy. J. Clin. Exp. Dent. 8, e201-e209. doi: 10.4317/jced.52917
28. Chen, P., Mancini, M., Sonis, S. T., Fernandez-Martinez, J., Liu, J., Cohen, E. E. W., et al. (2016). A novel peptide for simultaneously enhanced treatment of head and neck cancer and mitigation of oral mucositis. PLoS ONE 11:e0152995. doi: 10.1371/journal.pone.0152995
29. Chen, Y.-K., Hou, H.-A., Chow, J.-M., Chen, Y.-C., Hsueh, P.-R., and Tien, H.-F. (2011). The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur. J. Clin. Microbiol. Infect. Dis. 30, 753-759. doi: 10.1007/s10096-010-1148-z
30. Cho, H.-J., Park, Y. S., Kang, W. K., Kim, J.-W., and Lee, S.-Y. (2007). Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther. Drug Monit. 29, 190-196. doi: 10.1097/FTD.0b013e318040b1fe
31. Ciorba, M. A. (2012). A gastroenterologist's guide to probiotics. Clin. Gastroenterol. Hepatol. 10, 960-968. doi: 10.1016/j.cgh.2012.03.024
32. Ciorba, M. A., Hallemeier, C. L., Stenson, W. F., and Parikh, P. J. (2015). Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr. Opin. Support. Palliat. Care 9, 157-162. doi: 10.1097/SPC.0000000000000134
33. ClinicalTrials. gov (2016a). A Mouth Rinse Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis. Available at: https://clinicaltrials.gov/ct2/show/NCT02399228?term=NCT02399228/&rank=1 [accessed December 9, 2016]
34. ClinicalTrials. gov (2016b). Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02326675 [accessed December 13, 2016]
35. ClinicalTrials. gov (2016c). Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT01707641?term=NCT01707641&rank=1 [accessed December 9, 2016]
36. ClinicalTrials. gov (2016d). Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers. Available at: https://clinicaltrials.gov/ct2/show/NCT02868151?term=NCT02868151/&rank=1 [accessed December 9, 2016]
37. ClinicalTrials. gov (2016e). Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy. Available at: https://clinicaltrials.gov/ct2/show/NCT02300727?term=NCT02300727&rank=1 [accessed December 9, 2016]
38. ClinicalTrials. gov (2016f). Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects. Available at: https://clinicaltrials.gov/ct2/show/NCT01403064 [accessed December 7, 2016]
39. ClinicalTrials. gov (2016g). The Impact of Pentoxifylline and Vitamin E on Radiotherapy-Induced Toxicity in Head & Neck Cancer Patients. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02397486 [accessed December 9, 2016]
40. ClinicalTrials. gov (2017a). A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02508389 [accessed January 30, 2017]
41. ClinicalTrials. gov (2017b). Phase 2 Study to Evaluate the Safety & Efficacy of Brilacidin Oral Rinse in Patients With Head and Neck Cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02324335?term=brilacidin/&rank=1 [accessed January 30, 2017]
42. Cowen, D., Tardieu, C., Schubert, M., Peterson, D., Resbeut, M., Faucher, C., et al. (1997). Low energy Helium-Neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 38, 697-703. doi: 10.1016/S0360-3016(97)00076-X
43. Davila, M. L. (2006). Neutropenic enterocolitis. Curr. Opin. Gastroenterol. 22, 44-47
44. De Sanctis, V., Bossi, P., Sanguineti, G., Trippa, F., Ferrari, D., Bacigalupo, A., et al. (2016). Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus statements. Crit. Rev. Oncol. Hematol. 100, 147-166. doi: 10.1016/j.critrevonc.2016.01.010
45. Dodd, M. J., Dibble, S. L., Miaskowski, C., MacPhail, L., Greenspan, D., Paul, S. M., et al. (2000). Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy-induced mucositis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 90, 39-47. doi: 10.1067/moe.2000.105713
46. Douillard, J. Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., et al. (2014). Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 25, 1346-1355. doi: 10.1093/annonc/mdu141
47. El-Housseiny, A. A., Saleh, S. M., El-Masry, A. A., and Allam, A. A. (2007). The effectiveness of vitamin "E" in the treatment of oral mucositis in children receiving chemotherapy. J. Clin. Pediatr. Dent. 31, 167-170. doi: 10.17796/jcpd.31.3.r8371x45m42l10j7
48. Elting, L. S., Chang, Y.-C., Parelkar, P., Boers-Doets, C. B., Michelet, M., Hita, G., et al. (2013). Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support. Care Cancer Off. J. Multinatl. Assoc. Support. Care Cancer 21, 3243-3254. doi: 10.1007/s00520-013-1821-8
49. Elting, L. S., Cooksley, C., Chambers, M., Cantor, S. B., Manzullo, E., and Rubenstein, E. B. (2003). The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98, 1531-1539. doi: 10.1002/cncr.11671
50. Epstein, J. B., Silverman, S., Paggiarino, D. A., Crockett, S., Schubert, M. M., Senzer, N. N., et al. (2001). Benzydamine HCl for prophylaxis of radiation-induced oral mucositis: results from a multicenter, randomized, double-blind, placebo-controlled clinical trial. Cancer 92, 875-885. doi: 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1
51. Farrell, C. L., Bready, J. V., Rex, K. L., Chen, J. N., DiPalma, C. R., Whitcomb, K. L., et al. (1998). Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 58, 933-939
52. Ferreira, B., da Motta Silveira, F. M., and de Orange, F. A. (2016). Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic stem cell transplantation: a randomized clinical trial. Support. Care Cancer 24, 1035-1042. doi: 10.1007/s00520-015-2881-8
53. Ghoreishi, Z., Shidfar, F., Iravani, M., Esfahani, A., and Ghavamzadeh, A. (2007). Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation. Asia Pac. J. Clin. Oncol. 3, 113-118. doi: 10.1111/j.1743-7563.2007.00111.x
54. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Lond. Engl. 381, 303-312. doi: 10.1016/S0140-6736(12)61900-X
55. Han, X., Wu, Z., Di, J., Pan, Y., Zhang, H., Du, Y., et al. (2011). CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. Biomed. Pharmacother. Biomedecine Pharmacother. 65, 547-554. doi: 10.1016/j.biopha.2011.03.008
56. Hartmann, J. T., and Lipp, H.-P. (2003). Toxicity of platinum compounds. Expert Opin. Pharmacother. 4, 889-901. doi: 10.1517/14656566.4.6.889
57. Heinemann, V., Weikersthal, L. F., von Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., et al. (2014). FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1065-1075. doi: 10.1016/S1470-2045(14)70330-4
58. Hernández-Moreno, A., Vidal-Casariego, A., Calleja-Fernández, A., Kyriakos, G., Villar-Taibo, R., Urioste-Fondo, A., et al. (2015). Chronic enteritis in patients undergoing pelvic radiotherapy: prevalence, risk factors and associated complications. Nutr. Hosp. 32, 2178-2183. doi: 10.3305/nh.2015.32.5.9562
59. Kazemian, A., Kamian, S., Aghili, M., Hashemi, F. A., and Haddad, P. (2009). Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur. J. Cancer Care 18, 174-178. doi: 10.1111/j.1365-2354.2008.00943.x
60. Keefe, D. M., Elting, L. S., Nguyen, H. T., Grunberg, S. M., Aprile, G., Bonaventura, A., et al. (2014). Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother. Pharmacol. 74, 675-680. doi: 10.1007/s00280-014-2526-5
61. Koukourakis, M. I., and Maltezos, E. (2006). Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. Anticancer. Drugs 17, 133-138. doi: 10.1097/00001813-200602000-00003
62. Krishna, S. G., Zhao, W., Grazziutti, M. L., Sanathkumar, N., Barlogie, B., and Anaissie, E. J. (2011). Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients: clinical and research implications. Cancer 117, 648-655. doi: 10.1002/cncr.25633
63. Kudrimoti, M., Curtis, A., Azawi, S., Worden, F., Katz, S., Adkins, D., et al. (2016). Dusquetide: a novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J. Biotechnol. 239, 115-125. doi: 10.1016/j.jbiotec.2016.10.010
64. Kushner, J. A., Lawrence, H. P., Shoval, I., Kiss, T. L., Devins, G. M., Lee, L., et al. (2008). Development and validation of a Patient-Reported Oral Mucositis Symptom (PROMS) scale. J. Can. Dent. Assoc. 74, 59
65. Kwon, Y. (2016). Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. OncoTargets Ther. 9, 2007-2016. doi: 10.2147/OTT.S96899
66. Lalla, R. V., Bowen, J., Barasch, A., Elting, L., Epstein, J., Keefe, D. M., et al. (2014). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120, 1453-1461. doi: 10.1002/cncr.28592
67. Lalla, R. V., Gordon, G. B., Schubert, M., Silverman, S., Hutten, M., Sonis, S. T., et al. (2012). A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy. Support. Care Cancer 20, 1797-1804. doi: 10.1007/s00520-011-1277-7
68. Lee, W. J., Lee, J. L., Chang, S. E., Lee, M. W., Kang, Y. K., Choi, J. H., et al. (2009). Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br. J. Dermatol. 161, 1045-1051. doi: 10.1111/j.1365-2133.2009.09290.x
69. Limaye, S. A., Haddad, R. I., Cilli, F., Sonis, S. T., Colevas, A. D., Brennan, M. T., et al. (2013). Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119, 4268-4276. doi: 10.1002/cncr.28365
70. Logan, R. M., Stringer, A. M., Bowen, J. M., Gibson, R. J., Sonis, S. T., and Keefe, D. M. K. (2008). Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol. Ther. 7, 1139-1145. doi: 10.4161/cbt.7.7.6207
71. Mallick, S., Benson, R., and Rath, G. K. (2016). Radiation induced oral mucositis: a review of current literature on prevention and management. Eur. Arch. Otorhinolaryngol. 273, 2285-2293. doi: 10.1007/s00405-015-3694-6
72. Mayo, B. J., Stringer, A. M., Bowen, J. M., Bateman, E. H., and Keefe, D. M. (2017). Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analogues. Cancer Chemother. Pharmacol. 79, 233-249. doi: 10.1007/s00280-016-3165-9
73. Mego, M., Chovanec, J., Vochyanova-Andrezalova, I., Konkolovsky, P., Mikulova, M., Reckova, M., et al. (2015). Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study. Complement. Ther. Med. 23, 356-362. doi: 10.1016/j.ctim.2015.03.008
74. Meirovitz, A., Kuten, M., Billan, S., Abdah-Bortnyak, R., Sharon, A., Peretz, T., et al. (2010). Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer-a prospective pilot study. Radiat. Oncol. Lond. Engl. 5:16. doi: 10.1186/1748-717X-5-16
75. Meulendijks, D., Henricks, L. M., Sonke, G. S., Deenen, M. J., Froehlich, T. K., Amstutz, U., et al. (2015). Clinical relevance of DPYD variants c.1679T > G, c.1236G > A/HapB3, and c.1601G > A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 16, 1639-1650. doi: 10.1016/S1470-2045(15)00286-7
76. Moslehi, A., Taghizadeh-Ghehi, M., Gholami, K., Hadjibabaie, M., Jahangard-Rafsanjani, Z., Sarayani, A., et al. (2014). N-acetyl cysteine for prevention of oral mucositis in hematopoietic SCT: a double-blind, randomized, placebo-controlled trial. Bone Marrow Transplant. 49, 818-823. doi: 10.1038/bmt.2014.34
77. Nonzee, N. J., Dandade, N. A., Patel, U., Markossian, T., Agulnik, M., Argiris, A., et al. (2008). Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis?: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113, 1446-1452. doi: 10.1002/cncr.23714
78. Ozben, T. (2015). Antioxidant supplementation on cancer risk and concurrent use of antioxidants during cancer therapy: an update. Curr. Top. Med. Chem. 15, 170-178. doi: 10.2174/1568026615666141209160918
79. Peterson, D. E., Boers-Doets, C. B., Bensadoun, R. J., Herrstedt, J., and Esmo Guidelines Committee. (2015). Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 26(Suppl. 5), v139-v151. doi: 10.1093/annonc/mdv202
80. Peterson, D. E., Keefe, D. M., and Sonis, S. T. (2012). New frontiers in mucositis. Am. Soc. Clin. Oncol. Educ. Book 2012, 545-551. doi: 10.14694/EdBook_AM.2012.32.545
81. Pico, J., Avila-Garavito, A., and Naccache, P. (1998). Mucositis: its occurrence, consequences, and treatment in the oncology setting. Oncologist 3, 446-451
82. Prisciandaro, L. D., Geier, M. S., Butler, R. N., Cummins, A. G., and Howarth, G. S. (2011). Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol. Ther. 11, 671-677. doi: 10.4161/cbt.11.7.14896
83. Rao, N. G., Trotti, A., Kim, J., Schell, M. J., Zhao, X., Amdur, R. J., et al. (2014). Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 50, 765-769. doi: 10.1016/j.oraloncology.2014.06.001
84. Ribeiro, R. A., Wanderley, C. W. S., Wong, D. V. T., Mota, J. M. S. C., Leite, C. A. V. G., Souza, M. H. L. P., et al. (2016). Irinotecan-and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. Cancer Chemother. Pharmacol. 78, 881-893. doi: 10.1007/s00280-016-3139-y
85. Riley, P., Glenny, A.-M., Worthington, H. V., Littlewood, A., Clarkson, J. E., and McCabe, M. G. (2015). Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst. Rev. 23:CD011552. doi: 10.1002/14651858.CD011552.pub2
86. Riley, P., McCabe, M. G., and Glenny, A.-M. (2016). Oral cryotherapy for preventing oral mucositis in patients receiving cancer treatment. JAMA Oncol. 2, 1365-1366. doi: 10.1001/jamaoncol.2016.2680
87. Rm, L., Rj, G., St, S., and Dm, K. (2007). Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 43, 395-401. doi: 10.1016/j.oraloncology.2006.04.011
88. Roldan, C. J., Nouri, K., Chai, T., and Huh, B. (2017). Methylene blue for the treatment of intractable pain associated with oral mucositis. Pain Pract. doi: 10.1111/papr.12566 [Epub ahead of print]
89. Rubenstein, E. B., Peterson, D. E., Schubert, M., Keefe, D., McGuire, D., Epstein, J., et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100, 2026-2046. doi: 10.1002/cncr.20163
90. Rubin, J. S., Osada, H., Finch, P. W., Taylor, W. G., Rudikoff, S., and Aaronson, S. A. (1989). Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 86, 802-806. doi: 10.1073/pnas.86.3.802
91. Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., et al. (2014). Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann. Oncol. 25, 808-815. doi: 10.1093/annonc/mdu009
92. Rugo, H. S., Seneviratne, L., Beck, J. T., Glaspy, J. A., Peguero, J. A., Pluard, T. J., et al. (2016). Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial. J. Clin. Oncol. 34:189. doi: 10.1200/jco.2016.34.26_suppl.189
93. Sachak, T., Arnold, M. A., Naini, B. V., Graham, R. P., Shah, S. S., Cruise, M., et al. (2015). Neutropenic enterocolitis: new insights into a deadly entity. Am. J. Surg. Pathol. 39, 1635-1642. doi: 10.1097/PAS.0000000000000517
94. Sanguineti, G., Sormani, M. P., Marur, S., Gunn, G. B., Rao, N., Cianchetti, M., et al. (2012). Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer. Int. J. Radiat. Oncol. Biol. Phys. 83, 235-242. doi: 10.1016/j.ijrobp.2011.06.2000
95. Schubert, M. M., Eduardo, F. P., Guthrie, K. A., Franquin, J.-C., Bensadoun, R.-J. J., Migliorati, C. A., et al. (2007). A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support. Care Cancer 15, 1145-1154. doi: 10.1007/s00520-007-0238-7
96. Schwab, M., Zanger, U. M., Marx, C., Schaeffeler, E., Klein, K., Dippon, J., et al. (2008). Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 26, 2131-2138. doi: 10.1200/JCO.2006.10.4182
97. Shameem, R., Lacouture, M., and Wu, S. (2015). Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Invest. 33, 70-77. doi: 10.3109/07357907.2014.1001893
98. Sheibani, K. M., Mafi, A. R., Moghaddam, S., Taslimi, F., Amiran, A., and Ameri, A. (2015). Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac. J. Clin. Oncol. 11, 22-27. doi: 10.1111/ajco.12288
99. Shi, V. J., Levy, L. L., and Choi, J. N. (2016). Cutaneous manifestations of nontargeted and targeted chemotherapies. Semin. Oncol. 43, 419-425. doi: 10.1053/j.seminoncol.2016.02.018
100. Skof, E., Rebersek, M., Hlebanja, Z., and Ocvirk, J. (2009). Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer 9:120. doi: 10.1186/1471-2407-9-120
101. Sonis, S., Andreotta, P. W., and Lyng, G. (2017). On the pathogenesis of mTOR-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa. Oral Dis. 23, 347-352. doi: 10.1111/odi.12616
102. Sonis, S., Elting, L., Keefe, D., Nguyen, H., Grunberg, S., Randolph-Jackson, P., et al. (2015). Unanticipated frequency and consequences of regimen-related diarrhea in patients being treated with radiation or chemoradiation regimens for cancers of the head and neck or lung. Support. Care Cancer 23, 433-439. doi: 10.1007/s00520-014-2395-9
103. Sonis, S., Treister, N., Chawla, S., Demetri, G., and Haluska, F. (2010). Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116, 210-215. doi: 10.1002/cncr.24696
104. Sonis, S. T. (1998). Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol. 34, 39-43. doi: 10.1016/S1368-8375(97)00053-5
105. Sonis, S. T. (2002). The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit. Rev. Oral Biol. Med. 13, 380-389. doi: 10.1177/154411130201300502
106. Sonis, S. T. (2004). The pathobiology of mucositis. Nat. Rev. Cancer 4, 277-284. doi: 10.1038/nrc1318
107. Sonis, S. T. (2007). Pathobiology of oral mucositis: novel insights and opportunities. J. Support Oncol. 9 (Suppl 4), 3-11
108. Sonis, S. T. (2010). Regimen-related gastrointestinal toxicities in cancer patients. Curr. Opin. Support. Palliat. Care 4, 26-30. doi: 10.1097/SPC.0b013e328335fb76
109. Sonis, S. T. (2011). Oral Mucositis. Pocket Book for Cancer Supportive Care. London: Springer Healthcare
110. Sonis, S. T. (2013). Oral mucositis in head and neck cancer: risk, biology, and management. Am. Soc. Clin. Oncol. Educ. Book doi: 10.1200/EdBook_AM.2013.33.e236
111. Sonis, S. T., Eilers, J. P., Epstein, J. B., LeVeque, F. G., Liggett, W. H., Mulagha, M. T., et al. (1999). Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group. Cancer 85, 2103-2113. doi: 10.1002/(sici)1097-0142(19990515)85:10<2103::aid-cncr2>3.0.co;2-0
112. Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., et al. (2004). Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 1995-2025. doi: 10.1002/cncr.20162
113. Sonis, S. T., Hashemi, S., Epstein, J. B., Nair, R. G., and Raber-Durlacher, J. E. (2016). Could the biological robustness of low level laser therapy (Photobiomodulation) impact its use in the management of mucositis in head and neck cancer patients. Oral Oncol. 54, 7-14. doi: 10.1016/j.oraloncology.2016.01.005
114. Sonis, S. T., Tracey, C., Shklar, G., Jenson, J., and Florine, D. (1990). An animal model for mucositis induced by cancer chemotherapy. Oral Surg. Oral Med. Oral Pathol. 69, 437-443. doi: 10.1016/0030-4220(90)90376-4
115. Sorensen, J. B., Skovsgaard, T., Bork, E., Damstrup, L., and Ingeberg, S. (2008). Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer 112, 1600-1606. doi: 10.1002/cncr.23328
116. Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., et al. (2004). Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-2598. doi: 10.1056/NEJMoa040125
117. Squier, C. A., and Kremer, M. J. (2001). Biology of oral mucosa and esophagus. JNCI Monogr. 2001, 7-15. doi: 10.1093/oxfordjournals.jncimonographs.a003443
118. Stein, A., Voigt, W., and Jordan, K. (2010). Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2, 51-63. doi: 10.1177/1758834009355164
119. Stiff, P. J., Emmanouilides, C., Bensinger, W. I., Gentile, T., Blazar, B., Shea, T. C., et al. (2006a). Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J. Clin. Oncol. 24, 5186-5193. doi: 10.1200/JCO.2005.02.8340
120. Stiff, P. J., Erder, H., Bensinger, W. I., Emmanouilides, C., Gentile, T., Isitt, J., et al. (2006b). Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 37, 393-401. doi: 10.1038/sj.bmt.1705250
121. Stringer, A. M., Al-Dasooqi, N., Bowen, J. M., Tan, T. H., Radzuan, M., Logan, R. M., et al. (2013). Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support. Care Cancer 21, 1843-1852. doi: 10.1007/s00520-013-1741-7
122. Stringer, A. M., and Logan, R. M. (2015). The role of oral flora in the development of chemotherapy-induced oral mucositis. J. Oral Pathol. Med. 44, 81-87. doi: 10.1111/jop.12152
123. Svanberg, A., öhrn, K., and Birgegård, G. (2015). Caphosol(®) mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. Eur. J. Oncol. Nurs. 19, 50-53. doi: 10.1016/j.ejon.2014.07.011
124. Theis, V. S., Sripadam, R., Ramani, V., and Lal, S. (2010). Chronic radiation enteritis. Clin. Oncol. 22, 70-83. doi: 10.1016/j.clon.2009.10.003
125. Treister, N., Nieder, M., Baggott, C., Olson, E., Chen, L., Dang, H., et al. (2017). Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation. Br. J. Cancer 116, 21-27. doi: 10.1038/bjc.2016.380
126. Trotti, A., Bellm, L. A., Epstein, J. B., Frame, D., Fuchs, H. J., Gwede, C. K., et al. (2003). Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol. 66, 253-262. doi: 10.1016/S0167-8140(02)00404-8
127. Tsujimoto, T., Yamamoto, Y., Wasa, M., Takenaka, Y., Nakahara, S., Takagi, T., et al. (2015). L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol. Rep. 33, 33-39. doi: 10.3892/or.2014.3564
128. United States Department of Health and Human Services (2010). Common Terminology Criteria for Adverse Events (CTCAE)-CTCAE_4.03. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:8.5x11.pdf [accessed December 9, 2016]
129. Uçüncü, H., Ertekin, M. V., Yörük, O., Sezen, O., Ozkan, A., Erdogan, F., et al. (2006). Vitamin E and L-carnitine, separately or in combination, in the prevention of radiation-induced oral mucositis and myelosuppression: a controlled study in a rat model. J. Radiat. Res. 47, 91-102. doi: 10.1269/jrr.47.91
130. Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., et al. (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408-1417. doi: 10.1056/NEJMoa0805019
131. Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., et al. (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29, 2011-2019. doi: 10.1200/JCO.2010.33.5091
132. Van Sebille, Y. Z. A., Stansborough, R., Wardill, H. R., Bateman, E., Gibson, R. J., and Keefe, D. M. (2015). Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeutics. Curr. Oncol. Rep. 17:50. doi: 10.1007/s11912-015-0474-9
133. Vasconcelos, R. M., Sanfilippo, N., Paster, B. J., Kerr, A. R., Li, Y., Ramalho, L., et al. (2016). Host-microbiome cross-talk in oral mucositis. J. Dent. Res. 95, 725-733. doi: 10.1177/0022034516641890
134. Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Mahoney, M. R., O'Neil, B. H., et al. (2014). CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 32, 5s. doi: 10.1200/jco.2014.32.18_suppl.lba3
135. Viet, C. T., Corby, P. M., Akinwande, A., and Schmidt, B. L. (2014). Review of preclinical studies on treatment of mucositis and associated pain. J. Dent. Res. 93, 868-875. doi: 10.1177/0022034514540174
136. Villa, A., and Sonis, S. T. (2015). Mucositis: pathobiology and management. Curr. Opin. Oncol. 27, 159-164. doi: 10.1097/CCO.0000000000000180
137. Villa, A., and Sonis, S. T. (2016). Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin. Pharmacother. 17, 1801-1807. doi: 10.1080/14656566.2016.1217993
138. Wardill, H. R., Bowen, J. M., Al-Dasooqi, N., Sultani, M., Bateman, E., Stansborough, R., et al. (2014). Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biol. Ther. 15, 236-244. doi: 10.4161/cbt.27222
139. Webb, G. J., Brooke, R., and De Silva, A. N. (2013). Chronic radiation enteritis and malnutrition. J. Dig. Dis. 14, 350-357. doi: 10.1111/1751-2980.12061
140. Wong, K. H., Kuciejewska, A., Sharabiani, M. T. A., Ng-Cheng-Hin, B., Hoy, S., Hurley, T., et al. (2016). A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother. Oncol. 122, 207-211. doi: 10.1016/j.radonc.2016.06.015
141. Worthington, H. V., Clarkson, J. E., Bryan, G., Furness, S., Glenny, A.-M., Littlewood, A., et al. (2011). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst. Rev. 4:CD000978. doi: 10.1002/14651858.CD000978.pub5
142. Yamamoto, H., Ishihara, K., Takeda, Y., Koizumi, W., and Ichikawa, T. (2013). Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. BioMed Res. Int. 2013:276186. doi: 10.1155/2013/276186
143. Yuan, A., and Sonis, S. (2014). Emerging therapies for the prevention and treatment of oral mucositis. Expert Opin. Emerg. Drugs 19, 343-351. doi: 10.1517/14728214.2014.946403
144. Zecha, J. A. E. M., Raber-Durlacher, J. E., Nair, R. G., Epstein, J. B., Sonis, S. T., Elad, S., et al. (2016). Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. Support. Care Cancer 24, 2781-2792. doi: 10.1007/s00520-016-3152-z